These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 30353992)
21. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018. Lew FH; McQuown B; Borrego J; Cunningham S; Burgess KE Vet Comp Oncol; 2019 Dec; 17(4):465-471. PubMed ID: 31069932 [TBL] [Abstract][Full Text] [Related]
22. Confirmed case of Pneumocystis pneumonia in a Maltese Terrier × Papillon dog being treated with toceranib phosphate. Best MP; Boyd SP; Danesi P Aust Vet J; 2019 May; 97(5):162-165. PubMed ID: 31025329 [TBL] [Abstract][Full Text] [Related]
23. The role of toceranib phosphate in dogs with non-mast cell neoplasia: A systematic review. Frezoulis P; Harper A Vet Comp Oncol; 2022 Jun; 20(2):362-371. PubMed ID: 34981886 [TBL] [Abstract][Full Text] [Related]
24. Toceranib phosphate in the treatment of canine thyroid carcinoma: 42 cases (2009-2018). Sheppard-Olivares S; Bello NM; Wood E; Szivek A; Biller B; Hocker S; Wouda RM Vet Comp Oncol; 2020 Dec; 18(4):519-527. PubMed ID: 32012432 [TBL] [Abstract][Full Text] [Related]
25. Investigation of thyroid function in dogs treated with the tyrosine kinase inhibitor toceranib. Harper A; Blackwood L; Mason S Vet Comp Oncol; 2020 Sep; 18(3):433-437. PubMed ID: 31498949 [TBL] [Abstract][Full Text] [Related]
26. Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study. Pellin MA; Wouda RM; Robinson K; Tsimbas K; Kurzman ID; Biller BJ; Vail DM Vet Comp Oncol; 2017 Sep; 15(3):919-931. PubMed ID: 27146577 [TBL] [Abstract][Full Text] [Related]
27. A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis. Tani H; Miyamoto R; Noguchi S; Kurita S; Nagashima T; Michishita M; Yayoshi N; Tamura K; Bonkobara M BMC Vet Res; 2021 Apr; 17(1):147. PubMed ID: 33827546 [TBL] [Abstract][Full Text] [Related]
28. Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer. Leblanc AK; Miller AN; Galyon GD; Moyers TD; Long MJ; Stuckey AC; Wall JS; Morandi F Vet Radiol Ultrasound; 2012; 53(3):348-57. PubMed ID: 22360684 [TBL] [Abstract][Full Text] [Related]
29. Toceranib phosphate (Palladia) for the treatment of canine exocrine pancreatic adenocarcinoma. Musser ML; Johannes CM BMC Vet Res; 2021 Aug; 17(1):269. PubMed ID: 34380474 [TBL] [Abstract][Full Text] [Related]
30. A prospective, multi-centre, Veterinary Radiation Therapy Oncology Group study reveals potential efficacy of toceranib phosphate (Palladia) as a primary or adjuvant agent in the treatment of canine nasal carcinoma. Ehling TJ; Klein MK; Smith L; Prescott D; Haney S; Looper J; LaDue T; Brawner W; Fidel J; Shiomitsu K; Green E; Saba C; Turek M; Farrelly J Vet Comp Oncol; 2022 Mar; 20(1):293-303. PubMed ID: 34655275 [TBL] [Abstract][Full Text] [Related]
31. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma. Gardner HL; London CA; Portela RA; Nguyen S; Rosenberg MP; Klein MK; Clifford C; Thamm DH; Vail DM; Bergman P; Crawford-Jakubiak M; Henry C; Locke J; Garrett LD BMC Vet Res; 2015 Jun; 11():131. PubMed ID: 26062540 [TBL] [Abstract][Full Text] [Related]
32. Response and outcome following toceranib phosphate treatment for stage four anal sac apocrine gland adenocarcinoma in dogs: 15 cases (2013-2017). Elliott JW J Am Vet Med Assoc; 2019 Apr; 254(8):960-966. PubMed ID: 30938616 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of palliative therapy, alone or in combination with toceranib phosphate, in dogs diagnosed with metastatic or recurrent beta-cell neoplasia. Alonso-Miguel D; García-San José P; González Sanz S; Clarés Moral I; Pérez-Alenza MD N Z Vet J; 2021 Jul; 69(4):234-239. PubMed ID: 33944682 [TBL] [Abstract][Full Text] [Related]
34. Treatment of advanced-stage canine nasal carcinomas with toceranib phosphate: 23 cases (2015-2020). Merino-Gutierrez V; Borrego JF; Puig J; Hernández A; Clemente-Vicario F J Small Anim Pract; 2021 Oct; 62(10):881-885. PubMed ID: 34131916 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs. Heaton CM; Fernandes AFA; Jark PC; Pan X J Vet Intern Med; 2020 Mar; 34(2):873-881. PubMed ID: 31977135 [TBL] [Abstract][Full Text] [Related]
36. Assessment of postoperative adjuvant treatment using toceranib phosphate against adenocarcinoma in dogs. Yamazaki H; Tanaka T; Mie K; Nishida H; Miura N; Akiyoshi H J Vet Intern Med; 2020 May; 34(3):1272-1281. PubMed ID: 32267594 [TBL] [Abstract][Full Text] [Related]
37. Distribution, metabolism, and excretion of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in dogs. Yancey MF; Merritt DA; White JA; Marsh SA; Locuson CW J Vet Pharmacol Ther; 2010 Apr; 33(2):154-61. PubMed ID: 20444040 [TBL] [Abstract][Full Text] [Related]
38. Genetic alterations of KIT during clonal expansion and subsequent acquisition of resistance to toceranib in a canine mast cell tumor cell line. Kurita S; Miyamoto R; Tani H; Kobayashi M; Sasaki T; Tamura K; Bonkobara M J Vet Pharmacol Ther; 2019 Nov; 42(6):673-681. PubMed ID: 31553064 [TBL] [Abstract][Full Text] [Related]
39. Palmar-plantar erythrodysesthesia syndrome resulting from toceranib phosphate in a dog with apocrine gland anal sac adenocarcinoma: a case report. Kim E; Kim SS; Ryu MO J Vet Sci; 2023 Nov; 24(6):e76. PubMed ID: 37904638 [TBL] [Abstract][Full Text] [Related]
40. Retrospective evaluation of toceranib phosphate (Palladia) in the treatment of canine carcinomatosis and mesothelioma. Hicks KA; Leeper HJ; Curran KM Vet Comp Oncol; 2024 Jun; 22(2):245-254. PubMed ID: 38622074 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]